Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GUARDANT HEALTH, INC.

(GH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
116.53(c) 114.78(c) 114.22(c) 120.49(c) 120.94(c) Last
1 349 630 1 627 402 1 643 080 1 828 150 818 923 Volume
-0.99% -1.50% -0.49% +5.49% +0.37% Change
More quotes
Financials (USD)
Sales 2021 368 M - -
Net income 2021 -329 M - -
Net cash position 2021 246 M - -
P/E ratio 2021 -36,2x
Yield 2021 -
Sales 2022 507 M - -
Net income 2022 -293 M - -
Net cash position 2022 175 M - -
P/E ratio 2022 -41,7x
Yield 2022 -
Capitalization 12 230 M 12 230 M -
EV / Sales 2021 32,6x
EV / Sales 2022 23,8x
Nbr of Employees 864
Free-Float 95,6%
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and... 
More about the company
Ratings of Guardant Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GUARDANT HEALTH, INC.
06/08GUARDANT HEALTHá : Announces Appointment of Chris Freeman as Chief Commercial Of..
BU
06/04GUARDANT HEALTHá : Says New Data Confirms LUNAR-2 Blood Test 'Highly Accurate' f..
MT
06/04GUARDANT HEALTHá : Presents Data at 2021 ASCO Annual Meeting Showing Blood Test ..
BU
06/03GUARDANT HEALTHá : Goldman Sachs Starts Guardant Health at Buy With $160 Price T..
MT
05/28GUARDANT HEALTHá : Guardant360 Dx Approved by FDA as First Companion Diagnostic ..
MT
05/28GUARDANT HEALTHá : Guardant360« CDx Receives FDA Approval as First and Only Liqu..
BU
05/28GUARDANT HEALTHá : Sues California-Based Natera for Making 'Misleading' Statemen..
MT
05/28GUARDANT HEALTHá : Files Lawsuit Against Natera for Misleading Oncologists
BU
05/25GUARDANT HEALTHá : Wells Fargo Starts Guardant Health at Overweight With $145 Pr..
MT
05/24GUARDANT HEALTHá : FDA Approves First Targeted Therapy for Subset of Non-Small C..
AQ
05/21GUARDANT HEALTHá : Receives FDA Approval for Guardant360 CDx as Companion Diagno..
MT
05/21GUARDANT HEALTHá : Guardant360« CDx Receives FDA Approval as Companion Diagnosti..
BU
05/21JOHNSON & JOHNSONá : US FDA Approves Johnson & Johnson's Rybrevant for Lung Canc..
MT
05/21Janssen Pharma Gets FDA Approval for Lung Cancer Drug
DJ
05/20GUARDANT HEALTHá : to Participate in Upcoming June Investor Conferences
BU
More news
News in other languages on GUARDANT HEALTH, INC.
03/03GUARDANT HEALTHá : Guardant360« CDx Liquid Biopsy erhält die CE-Zertifizierung f..
03/02GUARDANT HEALTHá : La biopsie liquide Guardant360« CDx obtient le marquage CE po..
01/19GUARDANT HEALTHá : und das Vall d'Hebron Institute of Oncology geben Partnerscha..
01/19GUARDANT HEALTHá : et l'Institut d'oncologie de Vall d'Hebron annoncent un parte..
2019Vision Fund veut garantir un prêt par ses parts dans Uber
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 167,08 $
Last Close Price 120,94 $
Spread / Highest target 61,2%
Spread / Average Target 38,1%
Spread / Lowest Target -26,4%
EPS Revisions
Managers and Directors
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Michael Bell Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capitalization (M$)
GUARDANT HEALTH, INC.-6.16%12 230
EXACT SCIENCES CORPORATION-8.00%20 910
BGI GENOMICS CO., LTD.-7.00%7 659
INVITAE CORPORATION-25.33%6 239
ADAPTIVE BIOTECHNOLOGIES CORPORATION-34.45%5 438
CAREDX, INC25.95%4 750